A clinical trial recently produced data that an experimental drug called Namodenoson, developed in Israel, induces weight loss in experimental models and normalizes glucose levels. The study is being conducted by Dr. Rifaat Safad at the Hadassah Medical Center in...
Emerging Biopharma
Category
Emerging Biopharma Market Influence and the Changing CRO Landscape
Recently, TrialSite News commented on a telling IQVIA survey showcasing the rise of “Emerging Biopharma.” In what used to be solely the territory of “big pharma,” new agile, aggressive and often well-funded private equity-based emerging biopharma operate on the same...
The Drug Development Business is Changing: “Emerging Biopharma” Driving More Commercialization
IQVIA informs of an important trends in clinical research and drug approvals. Between 2005 and 2012, out of the 188 novel therapeutic agents approved by the FDA, 74 (36.8%) were approved on the basis of a single pivotal clinical trial. The report titled “The...